Wall Street consensus for Bristol Myers’s fourth quarter ending December 2025 calls for low‐single‐digit revenue growth compared with the prior year period, with analysts modeling near-flat total top line versus Q4 2024. On the earnings front, the average estimate centers on adjusted EPS of approximately $1.65, representing a mid‐single‐digit decline from the year‐ago $1.75 mark, as elevated R&D spending and integration costs weigh on margin expansion. Management has guided to continued investment in late‐stage oncology candidates, signaling a roughly 5% increase in R&D outlays sequentially, which could temper net income growth even if core sales hold steady.

Bristol Myers’s flagship immuno‐oncology therapy Opdivo is projected to deliver double‐digit revenue growth in Q4, driven by expanded label approvals in lung and renal indications, with analysts forecasting a 12% year-over-year uptick in global sales. This strength is offset by ongoing generic encroachment on the company’s long-standing cardiovascular and immunology franchises, which are expected to register high‐single-digit declines in quarterly sales. Investors will be watching uptake trends in recently launched combination regimens, where Opdivo plus Yervoy market share gains could help offset volume losses in off‐patent lines.

Recent 13F filings reveal that large institutions have modestly increased their stakes in Bristol Myers during Q3, with the largest fund boosting its position by nearly 10%, bringing its total holdings to just over 110,000 shares. Other notable investors such as global asset managers raised stakes by double-digit percentages, collectively driving institutional ownership to more than three-quarters of outstanding stock. In conjunction with its Q4 outlook, the company announced a quarterly dividend bump of 1.6%, marking the 11th consecutive annual increase and underpinning a yield of approximately 4.6% on a full-year basis.